glp-1 prior authorization criteria Sharing a chart from the next issue of Plain Medicine, my GLP-1 Market Access: PBM Prior

Compounded hormone therapy carries additional uncertainties around dosing precision, quality control, and regulatory oversight compared to FDA-approved formulations

In clinical trials, both exenatide and lixisenatide reduced body weight by 2.03.8 kg and reduced HbA 1c levels by 0.51.5% (5.51.6 mmol/mol) [23,24,25]

doi: 10.1016/j.mcna.2018.10.009 [DOI] [PubMed] [Google Scholar] 80

Many people notice gradual weight loss within the first month, while more noticeable and consistent results typically develop over several weeks to months of continued treatment

Want to learn more about gut health

During this appointment, your provider will: If approved, your provider will prescribe semaglutide and walk you through the next steps